The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson's Disease Mouse Models.

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology
Do-Yeon KimHee-Sun Kim

Abstract

MP-10 (PF-2545920) is a selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme highly enriched in the striatum, nucleus accumbens, olfactory tubercle, and substantia nigra. The therapeutic effect of MP-10 has been reported in psychiatric and neurodegenerative disorders such as schizophrenia, depression, and Huntington's disease. However, the effect of MP-10 in Parkinson's disease (PD) has not been reported to date. In this study, we examined the effect of MP-10 in neuroinflammation and PD mouse models. MP-10 inhibited nitric oxide, tumor necrosis factor alpha, and interleukin (IL)-6 production, while it promoted IL-10 production in lipopolysaccharide (LPS)-stimulated BV2 microglial cells. Subsequent western blot and reverse transcription polymerase chain reaction analyses showed that MP-10 reduced the mRNA and protein levels of inducible nitric oxide synthase, cyclooxygenase-2, proinflammatory cytokines, and matrix metalloproteinase-3, -8, and - 9 in LPS-stimulated BV2 cells. Further mechanistic studies revealed that MP-10 exerts anti-inflammatory effects by inhibiting the phosphorylation of c-Jun N-terminal kinase and Akt, reducing the activity of nuclear factor-kappa B/activator protein-1, and upregulating the nucle...Continue Reading

References

Apr 1, 1992·Journal of Neuroscience Research·V BocchiniH Kettenmann
Jun 5, 2003·Clinical Neuropharmacology·S CristinaClaudio Pacchetti
Jan 24, 2007·Physiological Reviews·Karen Bedard, Karl-Heinz Krause
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Gwenn A Garden, Thomas Möller
Aug 8, 2009·The Journal of Pharmacology and Experimental Therapeutics·Steven M GrauerNicholas J Brandon
Mar 23, 2010·Cell·Christopher K GlassFred H Gage
Jun 1, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eun-Jung LeeHee-Sun Kim
Jul 26, 2013·Expert Opinion on Therapeutic Targets·Wito RichterMarco Conti
Jan 2, 2014·F1000prime Reports·James C Cronk, Jonathan Kipnis
Jan 29, 2014·Nature Reviews. Neurology·He-Jin LeeSeung-Jae Lee
Jun 4, 2014·Journal of Neuroinflammation·Jonathan D CherryM Kerry O'Banion
Aug 28, 2014·Current Pharmaceutical Design·Lindsay S Wilson, Nicholas J Brandon
Jul 27, 2015·Brain : a Journal of Neurology·Flavia NiccoliniMarios Politis
Apr 3, 2016·The International Journal of Neuropsychopharmacology·Pim R A HeckmanJos Prickaerts
Apr 3, 2016·Glia·Damien D Pearse, Zoë A Hughes
Jul 13, 2016·Journal of Neurochemistry·Sigurlaug Sveinbjornsdottir
Mar 25, 2017·International Journal of Molecular Sciences·Eric P KnottDamien D Pearse
May 31, 2017·Frontiers in Aging Neuroscience·Gyun Jee Song, Kyoungho Suk
Jun 24, 2017·Frontiers in Aging Neuroscience·Sudhakar R Subramaniam, Howard J Federoff
Mar 10, 2018·Current Medicinal Chemistry·Agnieszka ZagorskaMaciej Pawlowski
Nov 30, 2018·Biomolecules & Therapeutics·Suk Ju ChoJin Won Hyun
Dec 6, 2019·Frontiers in Cellular Neuroscience·Cai-Yun LiuHong-Liang Zhang

❮ Previous
Next ❯

Citations

Jun 23, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Roberto ErroKailash P Bhatia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.